Old Web
English
Sign In
Acemap
>
authorDetail
>
Jan Hertel
Jan Hertel
Ruhr University Bochum
Bevacizumab
Oxaliplatin
Colorectal cancer
Medicine
Oncology
3
Papers
20
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial
2018
European Journal of Cancer
Susanna Hegewisch-Becker
Stefanie Nöpel-Dünnebacke
Axel Hinke
Ullrich Graeven
Anke Reinacher-Schick
Jan Hertel
Christian A. Lerchenmuller
B. Killing
R. Depenbusch
Salah-Eddin Al-Batran
Thoralf Lange
G. Dietrich
Andrea Tannapfel
Dirk Arnold
Show All
Source
Cite
Save
Citations (12)
Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial
2018
Clinical Colorectal Cancer
Stefanie Noepel-Duennebacke
Dirk Arnold
Jan Hertel
Andrea Tannapfel
Axel Hinke
Susanna Hegewisch-Becker
Anke Reinacher-Schick
Show All
Source
Cite
Save
Citations (4)
Localization of the primary tumor (LPT) and maintenance strategies after first line oxaliplatin (Ox), fluoropyrimidine (FP), and bevacizumab (Bev) in metastatic colorectal cancer (mCRC): Results from the AIO 0207 trial.
2017
Journal of Clinical Oncology
Anke Reinacher-Schick
Stefanie Noepel-Duennebacke
Jan Hertel
Andrea Tannapfel
Dirk Arnold
Axel Hinke
Susanna Hegewisch-Becker
Show All
Source
Cite
Save
Citations (4)
1